Dashboard
Manage Tickers

CERS CERUS CORP

Nasdaq cerus.com


$ 1.75 $ 0.13 (8.39 %)    

Tuesday, 11-Nov-2025 10:15:01 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 619.61 $ -0.93 (-0.15 %)
DIA $ 474.44 $ 0.33 (0.07 %)
SPY $ 679.41 $ -0.57 (-0.08 %)
TLT $ 89.85 $ -0.09 (-0.1 %)
GLD $ 379.07 $ -0.96 (-0.25 %)
$ 1.6
$ 1.61
$ 1.74 x 800
$ 1.75 x 1,313
$ 1.61 - $ 1.75
$ 1.12 - $ 2.24
1,434,162
na
307.34M
$ 1.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-05-2025 06-30-2025 10-Q
3 05-01-2025 03-31-2025 10-Q
4 02-26-2025 01-01-1970 10-K
5 10-31-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 03-05-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 03-01-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 02-22-2022 12-31-2021 10-K
17 11-02-2021 09-30-2021 10-Q
18 08-03-2021 06-30-2021 10-Q
19 05-04-2021 03-31-2021 10-Q
20 02-25-2021 12-31-2020 10-K
21 10-29-2020 09-30-2020 10-Q
22 08-05-2020 06-30-2020 10-Q
23 05-05-2020 03-31-2020 10-Q
24 02-21-2020 12-31-2019 10-K
25 10-30-2019 09-30-2019 10-Q
26 08-01-2019 06-30-2019 10-Q
27 05-07-2019 03-31-2019 10-Q
28 02-27-2019 12-31-2018 10-K
29 11-01-2018 09-30-2018 10-Q
30 08-02-2018 06-30-2018 10-Q
31 05-08-2018 03-31-2018 10-Q
32 03-08-2018 12-31-2017 10-K
33 11-03-2017 09-30-2017 10-Q
34 08-04-2017 06-30-2017 10-Q
35 05-04-2017 03-31-2017 10-Q
36 03-08-2017 12-31-2016 10-K
37 11-04-2016 09-30-2016 10-Q
38 08-05-2016 06-30-2016 10-Q
39 05-06-2016 03-31-2016 10-Q
40 03-09-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

correction-cerus-q3-eps-000-beats-003-estimate-sales-52698m-miss-54400m-estimate
CORRECTION: Cerus Q3 EPS $0.00 Beats $(0.0...
11/07/2025 00:09:29

Cerus (NASDAQ:CERS) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.03) by 103....

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
11/06/2025 21:06:30

cerus-raises-fy2025-sales-guidance-from-200000m-203000m-to-202000m-204000m-vs-210433m-est
Cerus Raises FY2025 Sales Guidance from $2...
11/06/2025 21:03:50

Cerus (NASDAQ:CERS) raises FY2025 sales outlook from $200.000 million-$203.000 million to $202.000 million-$204.000 million vs ...

earnings-scheduled-for-november-6-2025
Earnings Scheduled For November 6, 2025
11/06/2025 11:12:19

cerus-corporation-announces-german-blood-advisory-committees-recommendation-of-intercept-for-enhanced-platelet-transfusion-safety
Cerus Corporation Announces German Blood A...
08/25/2025 13:03:51

Cerus Corporation (NASDAQ:CERS) announced today the publication of a new recommendation from the German National Blood Advisory...

cerus-raises-fy2025-sales-guidance-from-19400m-20000m-to-20000m-20300m-vs-21380m-est
Cerus Raises FY2025 Sales Guidance from $1...
08/05/2025 20:02:12

Cerus (NASDAQ:CERS) raises FY2025 sales outlook from $194.00 million-$200.00 million to $200.00 million-$203.00 million vs $213...

cerus-q2-eps-003-inline-sales-5245m-miss-5263m-estimate
Cerus Q2 EPS $(0.03), Inline, Sales $52.45...
08/05/2025 20:01:44

Cerus (NASDAQ:CERS) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is unchanged ...

Core News & Articles
Earnings Scheduled For August 5, 2025
08/05/2025 08:32:54

cerus-awarded-addl-72m-contract-amendment-by-us-dod-ibas-program-for-development-of-lyophilized-pathogen-reduced-cryoprecipitated-fibrinogen-complex-to-treat-bleeding-due-to-trauma
Cerus Awarded Addl $7.2M Contract Amendmen...
07/21/2025 12:35:27

Additional Funding to Support Randomized Study Evaluating Earlier Access to INTERCEPT Fibrinogen Complex in Trauma Associated H...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
07/02/2025 21:05:48

cerus-notified-body-tv-sd-completes-review-of-clinical-module-for-ce-mark-submission-for-intercept-red-blood-cells
Cerus' Notified Body, TÜV-SÜD, Completes R...
07/02/2025 12:34:24

cerus-to-showcase-latest-intercept-blood-system-clinical-data-at-35th-regional-isbt-congress-being-held-may-31-to-june-4-2025-in-milan
Cerus To Showcase Latest INTERCEPT Blood S...
05/29/2025 12:37:04

Presentations and abstracts showcase the broad applicability and expected benefits of the INTERCEPT Blood System for platelets,...

cerus-announces-two-in-country-regulatory-approvals-for-int200
Cerus Announces Two In-Country Regulatory ...
05/28/2025 12:35:05

France and Switzerland approve INT200 for use with the INTERCEPT Blood System for Platelets and Plasma

cerus-affirms-fy2025-sales-guidance-of-19400m-20000m-vs-22192m-est
Cerus Affirms FY2025 Sales Guidance of $19...
05/01/2025 20:06:15

Cerus (NASDAQ:CERS) affirms FY2025 sales outlook from $194.00 million-$200.00 million to $194.00 million-$200.00 million vs $22...

cerus-q1-eps-004-inline-sales-4324m-miss-4962m-estimate
Cerus Q1 EPS $(0.04), Inline, Sales $43.24...
05/01/2025 20:05:56

Cerus (NASDAQ:CERS) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 20 perce...

Core News & Articles
Earnings Scheduled For May 1, 2025
05/01/2025 08:32:37

a-look-at-ceruss-upcoming-earnings-report
A Look at Cerus's Upcoming Earnings Report
04/30/2025 20:02:53

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
04/02/2025 21:05:37

cantor-fitzgerald-reiterates-overweight-on-cerus-maintains-4-price-target
Cantor Fitzgerald Reiterates Overweight on...
02/21/2025 17:32:28

Cantor Fitzgerald analyst Ross Osborn reiterates Cerus (NASDAQ:CERS) with a Overweight and maintains $4 price target.

cerus-q4-2024-gaap-eps-001-inline-sales-5675m-beat-4964m-estimate
Cerus Q4 2024 GAAP EPS $(0.01), Inline, Sa...
02/20/2025 21:02:47

Cerus (NASDAQ:CERS) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is unchanged ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION